A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

← catalyst calendar

NCT07024784 · readout ≤ 530 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →. With GOG Foundation.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

377estimated

Sites

Countries

Israel, Japan, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-07-30

actual

When the study began enrolling

Primary completion

Jan 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Feb 2028

estimated

The whole study's end, after follow-up

First posted

2025-06-17

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-02

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Gynecologic Cancers
Platinum-Sensitive Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer (PSOC)

Interventions

Drug: IMGN151
Drug: Carboplatin
Drug: Bevacizumab
Drug: Olaparib

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants With Dose-limiting Toxicities (DLTs)

measured Up to approximately 3 years

Percentage of Participants with Adverse Events (AE)

measured Up to approximately 3 years

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed